Have a personal or library account? Click to login
A Complex Interplay: Navigating the Crossroads of Tobacco Use, Cardiovascular Disease, and the COVID-19 Pandemic: A WHF Policy Brief Cover

A Complex Interplay: Navigating the Crossroads of Tobacco Use, Cardiovascular Disease, and the COVID-19 Pandemic: A WHF Policy Brief

Global Heart
Volume 19 (2024): Issue 1
By: Regina Dalmau,  Abdullah M. Alanazi,  Monika Arora,  Amitava Banerjee,  Eduardo Bianco,  Diann E. Gaalema,  Fastone M. Goma,  Koji Hasegawa,  Maki Komiyama,  Mónica Pérez Ríos,  Jeffrey Willett and  Yunshu Wang  
Open Access
|Jul 2024

References

  1. 1Institute for Health Metrics and Evaluation. GBD Compare. Glob Burd Dis. 2019. [cited 2023 September 1]. Available from: https://vizhub.healthdata.org/gbd-compare/.
    Back to article
  2. 2National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention (US); 2014.
    Back to article
  3. 3Hirvonen E, Karlsson A, Saaresranta T, Laitinen T. Documentation of the patient’s smoking status in common chronic diseases – analysis of medical narrative reports using the ULMFiT based text classification. Eur Clin Respir J. 2021; 8: 2004664. DOI: 10.1080/20018525.2021.2004664
    Back to article
  4. 4WHO Framework Convention on Tobacco Control, Conference of the Parties, Ninth Session. Decision: Declaration on WHO FCTC and Recovery from the COVID-19 Pandemic 2021.
    Back to article
  5. 5Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. J Med Virol. 2021; 93: 1045–1056. DOI: 10.1002/jmv.26389
    Back to article
  6. 6Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91–95. DOI: 10.1016/j.ijid.2020.03.017
    Back to article
  7. 7Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5: 811. DOI: 10.1001/jamacardio.2020.1017
    Back to article
  8. 8Mohamed MO, Banerjee A. Long COVID and cardiovascular disease: a learning health system approach. Nat Rev Cardiol. 2022; 19: 287–8. DOI: 10.1038/s41569-022-00697-7
    Back to article
  9. 9Jain U. Effect of COVID-19 on the Organs. Cureus. 2020; 12: e9540. DOI: 10.7759/cureus.9540
    Back to article
  10. 10Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS -CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020; 39: e105114. DOI: 10.15252/embj.20105114
    Back to article
  11. 11Komiyama M, Hasegawa K. Anticoagulant therapy for patients with coronavirus disease 2019: urgent need for enhanced awareness. Eur Cardiol Rev. 2020; 15: e58. DOI: 10.15420/ecr.2020.24
    Back to article
  12. 12World Health Organization. Smoking and COVID-19: scientific brief. World Health Organ 2020. [cited 2023 September 1]. Available from: https://www.who.int/news-room/commentaries/detail/smoking-and-covid-19.
    Back to article
  13. 13European Centre for Disease Prevention and Control. Coronavirus Disease 2019 (COVID-19) Pandemic: Increased Transmission in the EU/EEA and the UK – Seventh Update 2020.
    Back to article
  14. 14Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020; 253: 117723. DOI: 10.1016/j.lfs.2020.117723
    Back to article
  15. 15Malakan Rad E, Momtazmanesh S. COVID-19-induced silent myocarditis and newly developed hypertension in a 3-year-old boy. Egypt Heart J EHJ Off Bull Egypt Soc Cardiol. 2022; 74: 44. DOI: 10.1186/s43044-022-00282-w
    Back to article
  16. 16Bezati S, Velliou M, Ventoulis I, Simitsis P, Parissis J, Polyzogopoulou E. Infection as an under-recognized precipitant of acute heart failure: prognostic and therapeutic implications. Heart Fail Rev. 2023; 28: 893–904. DOI: 10.1007/s10741-023-10303-8
    Back to article
  17. 17Komiyama M, Hasegawa K, Matsumori A. Dilated cardiomyopathy risk in patients with coronavirus disease 2019: how to identify and characterise it early? Eur Cardiol Rev. 2020; 15: e49. DOI: 10.15420/ecr.2020.17
    Back to article
  18. 18Cohen BE, Edmondson D, Kronish IM. State of the art review: depression, stress, anxiety, and cardiovascular disease. Am J Hypertens. 2015; 28: 1295–1302. DOI: 10.1093/ajh/hpv047
    Back to article
  19. 19Perel P, Avezum A, Huffman M, Pais P, Rodgers A, Vedanthan R, et al. Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: the World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. Glob Heart. 2015; 10: 99. DOI: 10.1016/j.gheart.2015.04.003
    Back to article
  20. 20Arora M, ElSayed A, Beger B, Naidoo P, Shilton T, Jain N, et al. The impact of alcohol consumption on cardiovascular health: myths and measures. Glob Heart. 2022; 17: 45. DOI: 10.5334/gh.1132
    Back to article
  21. 21Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet. 2021; 398: 1700–1712. DOI: 10.1016/S0140-6736(21)02143-7
    Back to article
  22. 22United Nations. Policy brief: COVID-19 and the need for action on mental health 2020.
    Back to article
  23. 23United Nations. UN leads call to protect most vulnerable from mental health crisis during and after COVID-19. UN News 2020. [cited 2023 September 1]. Available from: https://news.un.org/en/story/2020/05/1063882.
    Back to article
  24. 24Czeisler MÉ, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic — United States, June 24–30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 1049–1057. DOI: 10.15585/mmwr.mm6932a1
    Back to article
  25. 25NHK. Suicide rates have reported a staggering 40% increase from the previous year, among women in particular. NHK 2020. [cited 2023 September 1]. Available from: https://www3.nhk.or.jp/news/html/20201110/k10012704501000.html.
    Back to article
  26. 26Starcke K, Brand M. Decision making under stress: A selective review. Neurosci Biobehav Rev. 2012; 36: 1228–1248. DOI: 10.1016/j.neubiorev.2012.02.003
    Back to article
  27. 27Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008; 1141: 105–130. DOI: 10.1196/annals.1441.030
    Back to article
  28. 28Komiyama M, Hasegawa K. Coronavirus disease 2019: psychological stress and cardiovascular diseases. Eur Cardiol. 2021; 16: e33. DOI: 10.15420/ecr.2021.10
    Back to article
  29. 29Patwardhan P. COVID-19: Risk of increase in smoking rates among England’s 6 million smokers and relapse among England’s 11 million ex-smokers. BJGP Open. 2020; 4: bjgpopen20X101067. DOI: 10.3399/bjgpopen20X101067
    Back to article
  30. 30Bommelé J, Hopman P, Hipple Walters B, Geboers C, Croes E, Fong G, et al. The double-edged relationship between COVID-19 stress and smoking: Implications for smoking cessation. Tob Induc Dis. 2020; 18. DOI: 10.18332/tid/125580
    Back to article
  31. 31Chen D. The psychosocial impact of the COVID-19 pandemic on changes in smoking behavior: Evidence from a nationwide survey in the UK. Tob Prev Cessat. 2020; 6: 1–5. DOI: 10.18332/tpc/126976
    Back to article
  32. 32Wiley RC, Oliver AC, Snow MB, Bunn JY, Barrows AJ, Tidey JW, et al. The impact of the Covid-19 pandemic on smoking among vulnerable populations. Nicotine Tob Res. 2023; 25: 282–290. DOI: 10.1093/ntr/ntac135
    Back to article
  33. 33National Research and Development Agency, National Cancer Center. Survey report on the new coronavirus and tobacco 2021.
    Back to article
  34. 34Rigotti NA, Chang Y, Regan S, Lee S, Kelley JHK, Davis E, et al. Cigarette smoking and risk perceptions during the COVID-19 pandemic reported by recently hospitalized participants in a smoking cessation trial. J Gen Intern Med. 2021; 36: 3786–3793. DOI: 10.1007/s11606-021-06913-3
    Back to article
  35. 35Nyman AL, Spears CA, Churchill V, Do VV, Henderson KC, Massey ZB, et al. Associations between COVID-19 risk perceptions and smoking and quitting behavior among U.S. adults. Addict Behav Rep. 2021; 14: 100394. DOI: 10.1016/j.abrep.2021.100394
    Back to article
  36. 36Gold AK, Hoyt DL, Milligan M, Hiserodt ML, Samora J, Leyro TM, et al. The role of fear of COVID-19 in motivation to quit smoking and reductions in cigarette smoking: a preliminary investigation of at-risk cigarette smokers. Cogn Behav Ther. 2021; 50: 295–304. DOI: 10.1080/16506073.2021.1877340
    Back to article
  37. 37World Health Organization. Pulse survey on continuity of essential health services during the COVID-19 pandemic - interim report: 27 August 2020. Geneva, Switzerland: World Health Organization; 2020.
    Back to article
  38. 38Baggio S, Vernaz N, Spechbach H, Salamun J, Jacquerioz F, Stringhini S, et al. Vulnerable patients forgo health care during the first wave of the Covid-19 pandemic. Prev Med. 2021; 150: 106696. DOI: 10.1016/j.ypmed.2021.106696
    Back to article
  39. 39Mafham MM, Spata E, Goldacre R, Gair D, Curnow P, Bray M, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. The Lancet. 2020; 396: 381–389. DOI: 10.1016/S0140-6736(20)31356-8
    Back to article
  40. 40De Filippo O, D’Ascenzo F, Angelini F, Bocchino PP, Conrotto F, Saglietto A, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. 2020; 383: 88–89. DOI: 10.1056/NEJMc2009166
    Back to article
  41. 41De Luca G, Algowhary M, Uguz B, Oliveira DC, Ganyukov V, Zimbakov Z, et al. COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. Heart Br Card Soc. 2022; 108: 458–466. DOI: 10.1136/heartjnl-2021-319750
    Back to article
  42. 42Rodríguez-Leor O, Cid-Álvarez B, Pérez de Prado A, Rossello X, Ojeda S, Serrador A, et al. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. Rev Espanola Cardiol Engl Ed. 2020; 73: 994–1002. DOI: 10.1016/j.rec.2020.08.002
    Back to article
  43. 43Lau JT, Griffiths S, Choi KC, Tsui HY. Avoidance behaviors and negative psychological responses in the general population in the initial stage of the H1 N1 pandemic in Hong Kong. BMC Infect Dis. 2010; 10: 139. DOI: 10.1186/1471-2334-10-139
    Back to article
  44. 44Ghisi GL de M, Xu Z, Liu X, Mola A, Gallagher R, Babu AS, et al. Impacts of the COVID-19 pandemic on cardiac rehabilitation delivery around the world. Glob Heart. 2021; 16: 43. DOI: 10.5334/gh.939
    Back to article
  45. 45Varghese MS, Beatty AL, Song Y, Xu J, Sperling LS, Fonarow GC, et al. Cardiac rehabilitation and the COVID-19 pandemic: persistent declines in cardiac rehabilitation participation and access among US medicare beneficiaries. Circ Cardiovasc Qual Outcomes. 2022; 15. DOI: 10.1161/CIRCOUTCOMES.122.009618
    Back to article
  46. 46Bandi P, Asare S, Majmundar A, Xue Z, Han X, Westmaas JL, et al. Changes in smoking cessation–related behaviors among US adults during the COVID-19 pandemic. JAMA Netw Open. 2022; 5: e2225149. DOI: 10.1001/jamanetworkopen.2022.25149
    Back to article
  47. 47Pettigrew S, Jun M, Roberts I, Bullen C, Nallaiah K, Rodgers A. Preferences for tobacco cessation information and support during Covid-19. J Addict Med. 2020; 14: e362–365. DOI: 10.1097/ADM.0000000000000743
    Back to article
  48. 48Kayhan Tetik B, Gedik Tekinemre I, Taş S. The effect of the COVID-19 Pandemic on smoking cessation success. J Community Health. 2021; 46: 471–475. DOI: 10.1007/s10900-020-00880-2
    Back to article
  49. 49Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M, et al. Cancer and COVID-19: analysis of patient outcomes. Future Oncol. 2021; 17: 3499–3510. DOI: 10.2217/fon-2021-0121
    Back to article
  50. 50Bellan M, Patti G, Hayden E, Azzolina D, Pirisi M, Acquaviva A, et al. Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Sci Rep. 2020; 10: 20731. DOI: 10.1038/s41598-020-77698-4
    Back to article
  51. 51Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K, et al. Clinical characteristics and predictors of 28-day mortality in 352 critically ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health. 2020; 11: 98. DOI: 10.2991/jegh.k.200928.001
    Back to article
  52. 52Kelly G, Petti S, Noah N. Covid-19, non-Covid-19 and excess mortality rates not comparable across countries. Epidemiol Infect. 2021; 149: e176. DOI: 10.1017/S0950268821001850
    Back to article
  53. 53Monteiro AC, Suri R, Emeruwa IO, Stretch RJ, Cortes-Lopez RY, Sherman A, et al. Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: A retrospective, observational cohort study. PLOS ONE. 2020; 15: e0238552. DOI: 10.1371/journal.pone.0238552
    Back to article
  54. 54Ferrari BL, Ferreira CG, Menezes M, De Marchi P, Canedo J, Melo ACD, et al. Determinants of COVID-19 mortality in patients with cancer from a community oncology practice in Brazil. JCO Glob Oncol. 2021: 46–55. DOI: 10.1200/GO.20.00444
    Back to article
  55. 55Ayhan M, Odabas H, Turan N, Ozyukseler DT, Kostek O, Alkan G, et al. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center’s experience. J Chemother. 2021; 33: 499–508. DOI: 10.1080/1120009X.2021.1923153
    Back to article
  56. 56Khalil A, Dhingra R, Al-Mulki J, Hassoun M, Alexis N. Questioning the sex-specific differences in the association of smoking on the survival rate of hospitalized COVID-19 patients. PLOS ONE. 2021; 16: e0255692. DOI: 10.1371/journal.pone.0255692
    Back to article
  57. 57Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almehmadi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLOS ONE. 2020; 15: e0233147. DOI: 10.1371/journal.pone.0233147
    Back to article
  58. 58Lacedonia D, Scioscia G, Santomasi C, Fuso P, Carpagnano GE, Portacci A, et al. Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients. Sci Rep. 2021; 11: 19251. DOI: 10.1038/s41598-021-98749-4
    Back to article
  59. 59Altschul DJ, Esenwa C, Haranhalli N, Unda SR, De La Garza Ramos R, Dardick J, et al. Predictors of mortality for patients with COVID-19 and large vessel occlusion. Interv Neuroradiol. 2020; 26: 623–628. DOI: 10.1177/1591019920954603
    Back to article
  60. 60Ho KS, Narasimhan B, Sheehan J, Wu L, Fung JY. Controversy over smoking in COVID-19—a real world experience in New York city. J Med Virol. 2021; 93: 4537–4543. DOI: 10.1002/jmv.26738
    Back to article
  61. 61Baskaran V, Murray RL, Hunter A, Lim WS, McKeever TM. Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. PLOS ONE. 2019; 14: e0220204. DOI: 10.1371/journal.pone.0220204
    Back to article
  62. 62Han L, Ran J, Mak Y-W, Suen LK-P, Lee PH, Peiris JSM, et al. Smoking and influenza-associated morbidity and mortality: a systematic review and meta-analysis. Epidemiology. 2019; 30: 405–417. DOI: 10.1097/EDE.0000000000000984
    Back to article
  63. 63López-Hernández Y, Rivas-Santiago CE, López JA, Mendoza-Almanza G, Hernandez-Pando R. Tuberculosis and cigarette smoke exposure: An update of in vitro and in vivo studies. Exp Lung Res. 2018; 44: 113–126. DOI: 10.1080/01902148.2018.1444824
    Back to article
  64. 64Nyunoya T, Mebratu Y, Contreras A, Delgado M, Chand HS, Tesfaigzi Y. Molecular processes that drive cigarette smoke-induced epithelial cell fate of the lung. Am J Respir Cell Mol Biol. 2014; 50: 471–482. DOI: 10.1165/rcmb.2013-0348TR
    Back to article
  65. 65Benowitz NL, Goniewicz ML, Halpern-Felsher B, Krishnan-Sarin S, Ling PM, O’Connor RJ, et al. Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19: current understanding and recommendations for future research. Lancet Respir Med. 2022; 10: 900–15. DOI: 10.1016/S2213-2600(22)00182-5
    Back to article
  66. 66Ministry of Health, Labour and Welfare of Japan. Benefits of quitting smoking. E-Heal 2020. [cited 2023 October 3]. Available from: https://www.e-healthnet.mhlw.go.jp/information/tobacco/t-08-001.html.
    Back to article
  67. 67Lung Foundation Australia. Quitting smoking. Lung Found Aust. n.d. [cited 2023 October 3]. Available from: https://lungfoundation.com.au/lung-health/protecting-your-lungs/quitting-smoking/.
    Back to article
  68. 68Rainer T, Smit D, Cameron P. Smoking and severe acute respiratory syndrome. Hong Kong J Emerg Med. 2004; 11: 143–145. DOI: 10.1177/102490790401100303
    Back to article
  69. 69Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, et al. Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis. 2016; 22: 49–55. DOI: 10.3201/eid2201.151340
    Back to article
  70. 70Nam H-S, Park JW, Ki M, Yeon M-Y, Kim J, Kim SW. High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea. Int J Infect Dis. 2017; 58: 37–42. DOI: 10.1016/j.ijid.2017.02.008
    Back to article
  71. 71Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. 2021; 116: 1319–1368. DOI: 10.1111/add.15276
    Back to article
  72. 72CDC COVID-19 Response Team, CDC COVID-19 Response Team, Chow N, Fleming-Dutra K, Gierke R, Hall A, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 382–386. DOI: 10.15585/mmwr.mm6913e2
    Back to article
  73. 73Samet JM. Tobacco products and the risks of SARS-CoV-2 infection and COVID-19. Nicotine Tob Res. 2020; 22: S93–S95. DOI: 10.1093/ntr/ntaa187
    Back to article
  74. 74Van Westen-Lagerweij NA, Meijer E, Meeuwsen EG, Chavannes NH, Willemsen MC, Croes EA. Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth. Npj Prim Care Respir Med. 2021; 31: 10. DOI: 10.1038/s41533-021-00223-1
    Back to article
  75. 75Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708–1720. DOI: 10.1056/NEJMoa2002032
    Back to article
  76. 76Miyara M, Tubach F, Pourcher V, Morélot-Panzini C, Pernet J, Haroche J, et al. Lower rate of daily smokers with symptomatic COVID-19: a monocentric self-report of smoking habit study. Front Med. 2022; 8: 668995. DOI: 10.3389/fmed.2021.668995
    Back to article
  77. 77World Health Organization. Post COVID-19 condition (Long COVID). World Health Organ 2022. [cited 2023 September 1]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:~:text=Definition,months%20with%20no%20other%20explanation.
    Back to article
  78. 78Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 2022; 376: e068993. DOI: 10.1136/bmj-2021-068993
    Back to article
  79. 79Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis Lond Engl. 2021; 53: 737–754. DOI: 10.1080/23744235.2021.1924397
    Back to article
  80. 80Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022; 28: 1706–1714. DOI: 10.1038/s41591-022-01909-w
    Back to article
  81. 81Hossain MA, Hossain KMA, Saunders K, Uddin Z, Walton LM, Raigangar V, et al. Prevalence of long COVID symptoms in Bangladesh: a prospective inception cohort study of COVID-19 survivors. BMJ Glob Health. 2021; 6: e006838. DOI: 10.1136/bmjgh-2021-006838
    Back to article
  82. 82Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022; 13: 1957. DOI: 10.1038/s41467-022-29521-z
    Back to article
  83. 83Paul E, Fancourt D. Health behaviours the month prior to COVID-19 infection and the development of self-reported long COVID and specific long COVID symptoms: a longitudinal analysis of 1581 UK adults. BMC Public Health. 2022; 22: 1716. DOI: 10.1186/s12889-022-14123-7
    Back to article
  84. 84Takakura K, Suka M, Kajihara M, Koido S. Clinical features, therapeutic outcomes, and recovery period of long COVID. J Med Virol. 2023; 95: e28316. DOI: 10.1002/jmv.28316
    Back to article
  85. 85Liu W, Tao Z-W, Wang L, Yuan M-L, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020; 133: 1032–1038. DOI: 10.1097/CM9.0000000000000775
    Back to article
  86. 86Egbe CO, Ngobese SP, Barca H, Crosbie E. “Are they trying to control us people?”: News media coverage of COVID-19 lockdown tobacco sales ban in South Africa. PLOS ONE. 2022; 17: e0278888. DOI: 10.1371/journal.pone.0278888
    Back to article
  87. 87Chen Z, Peto R, Zhou M, Iona A, Smith M, Yang L, et al. Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies. The Lancet. 2015; 386: 1447–1456. DOI: 10.1016/S0140-6736(15)00340-2
    Back to article
  88. 88The tobacco atlas. Challenges: COVID-19. Tob Atlas 2022. [cited 2023 September 1]. Available from: https://tobaccoatlas.org/challenges/covid-19/.
    Back to article
  89. 89Vardavas C, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020; 18. DOI: 10.18332/tid/119324
    Back to article
  90. 90Tobacco Reporter. BAT Unaffected by Virus Outbreak. Tob Report 2020. [cited 2023 September 1]. Available from: https://tobaccoreporter.com/2020/03/19/bat-unaffected-by-outbreak/.
    Back to article
  91. 91Williams S. Coronavirus income stocks: 7 high-yield dividend stocks to buy right now. Nasdaq 2020. [cited 2023 September 1]. Available from: https://www.nasdaq.com/articles/coronavirus-income-stocks%3A-7-high-yield-dividend-stocks-to-buy-right-now-2020-03-23.
    Back to article
  92. 92Tobacco tactics. Kenya- Country Profile. Tob Tactics 2021. [cited 2023 September 1]. Available from: https://tobaccotactics.org/article/kenya-country-profile/.
    Back to article
  93. 93Huber L, Cuadrado U, Fernandez-Megina R, Raw M, Marquizo AB, Romeo-Stuppy K. The impact of COVID-19 on the WHO FCTC, cessation, and tobacco policy. Tob Induc Dis. 2020; 18: 102. DOI: 10.18332/tid/130779
    Back to article
  94. 94Chen DT-H. Tobacco control measures in COVID-19 recovery: an opportune time to restore equity and planetary health. Environ Health Prev Med. 2022; 27: 15. DOI: 10.1265/ehpm.21-00027
    Back to article
  95. 95WHO Framework Convention on Tobacco Control, World Health Organization. WHO framework convention on tobacco control 2003: 36.
    Back to article
  96. 96El-Awa F, Fraser CP, Adib K, Hammerich A, Abdel Latif N, Fayokun R, et al. The necessity of continuing to ban tobacco use in public places post-COVID-19. East Mediterr Health J Rev Sante Mediterr Orient Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit. 2020; 26: 630–632. DOI: 10.26719/emhj.20.071
    Back to article
  97. 97González-Rábago Y, Cabezas-Rodríguez A, Martín U. Social inequalities in health determinants in Spanish children during the COVID-19 lockdown. Int J Environ Res Public Health. 2021; 18: 4087. DOI: 10.3390/ijerph18084087
    Back to article
  98. 98Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015; 132: 873–898. DOI: 10.1161/CIR.0000000000000228
    Back to article
  99. 99Roger VL. Medicine and society: social determinants of health and cardiovascular disease. Eur Heart J. 2020; 41: 1179–1181. DOI: 10.1093/eurheartj/ehaa134
    Back to article
  100. 100Tee GH, Aris T, Rarick J, Irimie S. Social determinants of health and tobacco use in five low and middle-income countries—results from the Global Adult Tobacco Survey (GATS), 2011–2012. Asian Pac J Cancer Prev APJCP. 2016; 17: 1269–1276. DOI: 10.7314/APJCP.2016.17.3.1269
    Back to article
  101. 101Abdulrahim S, Jawad M. Socioeconomic differences in smoking in Jordan, Lebanon, Syria, and Palestine: A cross-sectional analysis of national surveys. PloS One. 2018; 13: e0189829. DOI: 10.1371/journal.pone.0189829
    Back to article
  102. 102World Health Organization Regional Office for South-East Asia. Factsheet 2018: India 2018.
    Back to article
  103. 103Siddiqi K, Husain S, Vidyasagaran A, Readshaw A, Mishu MP, Sheikh A. Global burden of disease due to smokeless tobacco consumption in adults: an updated analysis of data from 127 countries. BMC Med. 2020; 18: 222. DOI: 10.1186/s12916-020-01677-9
    Back to article
  104. 104Tata Institute of Social Sciences, Ministry of Health and Family Welfare of India. Global adult tobacco survey—second round—India 2016–17 Report. New Delhi: Ministry of Health and Family Welfare of India; 2018.
    Back to article
  105. 105World Health Organization. Coronavirus disease (COVID-19): tobacco. World Health Organ 2022. [cited 2023 September 1]. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-tobacco.
    Back to article
  106. 106Arora M, Nazar GP, Sharma N, Jain N, Davidson F, Mohan S, et al. COVID-19 and tobacco cessation: lessons from India. Public Health. 2022; 202: 93–99. DOI: 10.1016/j.puhe.2021.11.010
    Back to article
  107. 107Sharma N, Chopra M, Bauld L, Nazar G, Joshi N, Chugh A, et al. Impact of a tobacco sales ban on the frequency of tobacco consumption in India during the COVID-19 pandemic. Tob Induc Dis. 2023; 21: 1–6. DOI: 10.18332/tid/161855
    Back to article
  108. 108WHO Framework Convention on Tobacco Control. 2021 global progress report on implementation of the WHO Framework Convention on Tobacco Control. Geneva: World Health Organization; 2022.
    Back to article
  109. 109Burki TK. Tobacco industry influence during the COVID-19 pandemic. Lancet Oncol. 2021; 22: 1658. DOI: 10.1016/S1470-2045(21)00644-6
    Back to article
  110. 110WHO Framework Convention on Tobacco Control. Guidelines for implementation of Article 5.3 2013.
    Back to article
  111. 111WHO Framework Convention on Tobacco Control. FCTC—overview. WHO Framew Conv Tob Control 2023. [cited 2023 September 1]. Available from: https://fctc.who.int/who-fctc/overview.
    Back to article
  112. 112Lee JJ, Wang MP, Yang SC. Will the tobacco industry ultimately triumph in the midst of COVID-19 pandemic?: A call for nurses’ action in tobacco control. Int J Nurs Stud. 2021; 115: 103726. DOI: 10.1016/j.ijnurstu.2020.103726
    Back to article
DOI: https://doi.org/10.5334/gh.1334 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Feb 7, 2024
Accepted on: Jun 10, 2024
Published on: Jul 1, 2024
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Tobacco,
cardiovascular disease,
COVID-19

© 2024 Regina Dalmau, Abdullah M. Alanazi, Monika Arora, Amitava Banerjee, Eduardo Bianco, Diann E. Gaalema, Fastone M. Goma, Koji Hasegawa, Maki Komiyama, Mónica Pérez Ríos, Jeffrey Willett, Yunshu Wang, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 19 (2024): Issue 1Next article